Total Payments
$36,855
2024 Payments
$2,895
Companies
58
Transactions
886
Medicare Patients
3,865
Medicare Billing
$1.4M
Payment Breakdown by Category
Research$21,186 (57.5%)
Food & Beverage$15,443 (41.9%)
Education$186.50 (0.5%)
Other$39.03 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21,186 | 14 | 57.5% |
| Food and Beverage | $15,443 | 868 | 41.9% |
| Education | $186.50 | 2 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39.03 | 2 | 0.1% |
Payments by Type
Research
$21,186
14 transactions
General
$15,669
872 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $22,082 | 78 | $0 (2024) |
| ABBVIE INC. | $4,280 | 240 | $0 (2024) |
| Allergan, Inc. | $1,175 | 79 | $0 (2022) |
| Teva Pharmaceuticals USA, Inc. | $985.48 | 60 | $0 (2024) |
| Amgen Inc. | $926.16 | 33 | $0 (2023) |
| Neurelis, Inc. | $916.25 | 49 | $0 (2024) |
| Lilly USA, LLC | $701.26 | 41 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $610.36 | 26 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $564.61 | 39 | $0 (2022) |
| Lundbeck LLC | $560.60 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,895 | 164 | ABBVIE INC. ($1,249) |
| 2023 | $24,012 | 179 | PFIZER INC. ($21,614) |
| 2022 | $2,757 | 160 | ABBVIE INC. ($805.95) |
| 2021 | $2,931 | 151 | AbbVie Inc. ($935.66) |
| 2020 | $1,710 | 93 | Allergan, Inc. ($553.00) |
| 2019 | $852.33 | 60 | Allergan Inc. ($147.76) |
| 2018 | $1,244 | 55 | Teva Pharmaceuticals USA, Inc. ($298.14) |
| 2017 | $453.82 | 24 | Allergan Inc. ($84.25) |
All Payment Transactions
886 individual payment records from CMS Open Payments — Page 3 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/02/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $9.92 | General |
| Category: NEUROSCIENCE | ||||||
| 08/01/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $29.09 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/30/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: Neuroscience | ||||||
| 07/30/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.30 | General |
| Category: NEUROSCIENCE | ||||||
| 07/29/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $27.13 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 07/26/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $34.30 | General |
| Category: NEUROSCIENCE | ||||||
| 07/25/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.80 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $31.31 | General |
| Category: NEUROSCIENCE | ||||||
| 07/18/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: NEUROSCIENCE | ||||||
| 07/16/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $26.39 | General |
| Category: Neuroscience | ||||||
| 07/16/2024 | MDD US Operations, LLC | Apokyn (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: APOMORPHINE HYDROCHLORIDE | ||||||
| 07/16/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: NEUROSCIENCE | ||||||
| 07/16/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $9.19 | General |
| Category: NEUROSCIENCE | ||||||
| 07/16/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $2.43 | General |
| Category: Neuroscience | ||||||
| 07/11/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Immunology | ||||||
| 07/11/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.30 | General |
| Category: NEUROSCIENCE | ||||||
| 07/10/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: NEUROSCIENCE | ||||||
| 07/03/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.90 | General |
| Category: NEUROSCIENCE | ||||||
| 07/02/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $9.31 | General |
| Category: NEUROSCIENCE | ||||||
| 06/28/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $34.09 | General |
| Category: NEUROSCIENCE | ||||||
| 06/24/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $3.36 | General |
| Category: NEUROSCIENCE | ||||||
| 06/19/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: PAIN | ||||||
| 06/18/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $26.83 | General |
| Category: Central Nervous System | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $8,915 | 9 |
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $7,014 | 3 |
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $5,257 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,286 | 76,691 | $857,409 | $610,986 |
| 2022 | 20 | 1,054 | 24,374 | $449,404 | $327,048 |
| 2021 | 16 | 972 | 16,356 | $371,647 | $274,429 |
| 2020 | 13 | 553 | 9,094 | $205,798 | $148,143 |
Total Patients
3,865
Total Services
126,515
Medicare Billing
$1.4M
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 93 | 74,890 | $506,785 | $372,292 | 73.5% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 72 | 159 | $43,199 | $31,687 | 73.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 183 | 281 | $46,365 | $29,905 | 64.5% |
| 95813 | Measurement of brain wave activity (eeg), 61-119 minutes | Office | 2023 | 66 | 66 | $36,300 | $26,391 | 72.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 73 | 260 | $36,400 | $23,093 | 63.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 148 | 148 | $31,080 | $21,341 | 68.7% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2023 | 95 | 95 | $31,851 | $19,252 | 60.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 104 | 104 | $25,552 | $15,185 | 59.4% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 57 | 57 | $20,611 | $14,755 | 71.6% |
| 93892 | Ultrasound of within the brain blood flow for blood clots | Office | 2023 | 94 | 94 | $19,516 | $14,237 | 73.0% |
| 76942 | Ultrasonic guidance for needle placement | Office | 2023 | 94 | 206 | $14,134 | $10,684 | 75.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 82 | 133 | $15,150 | $10,572 | 69.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 32 | 32 | $13,520 | $10,291 | 76.1% |
| 64640 | Destruction of peripheral nerve or branch | Office | 2023 | 15 | 26 | $7,920 | $5,832 | 73.6% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 15 | 30 | $3,552 | $2,149 | 60.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 31 | 34 | $2,550 | $1,755 | 68.8% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 14 | 25 | $2,335 | $1,117 | 47.9% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 18 | 51 | $590.00 | $447.08 | 75.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 45 | 22,900 | $144,270 | $112,091 | 77.7% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 63 | 64 | $35,840 | $27,564 | 76.9% |
| 93886 | Complete ultrasound of within the brain blood flow | Office | 2022 | 105 | 106 | $35,539 | $22,259 | 62.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 59 | 206 | $28,840 | $19,625 | 68.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 105 | 155 | $25,575 | $16,654 | 65.1% |
| 93892 | Ultrasound of within the brain blood flow for blood clots | Office | 2022 | 103 | 104 | $21,592 | $16,627 | 77.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 112 | 112 | $23,520 | $16,517 | 70.2% |
About Artem Kaplan, M.D., PH.D
Artem Kaplan, M.D., PH.D is a Neurology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2012. The National Provider Identifier (NPI) number assigned to this provider is 1477808590.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Artem Kaplan, M.D., PH.D has received a total of $36,855 in payments from pharmaceutical and medical device companies, with $2,895 received in 2024. These payments were reported across 886 transactions from 58 companies. The most common payment nature is "" ($21,186).
As a Medicare-enrolled provider, Kaplan has provided services to 3,865 Medicare beneficiaries, totaling 126,515 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location New York, NY
- Active Since 07/14/2012
- Last Updated 11/21/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1477808590
Products in Payments
- NURTEC ODT (Drug) $14,185
- ZAVZPRET (Drug) $8,915
- UBRELVY (Drug) $2,516
- QULIPTA (Drug) $1,879
- VALTOCO (Drug) $916.25
- BOTOX (Biological) $856.45
- Aimovig (Biological) $821.96
- EMGALITY (Drug) $551.92
- VYEPTI (Biological) $499.79
- MIGRANAL (Drug) $302.11
- AJOVY (Biological) $273.80
- AUSTEDO (Drug) $273.63
- AUBAGIO (Drug) $233.07
- AIMOVIG (Biological) $221.22
- ONZETRA Xsail (Drug) $204.00
- Austedo XR (Drug) $193.42
- ADUHELM (Biological) $178.10
- NUEDEXTA (Drug) $162.36
- Dysport (Drug) $148.01
- Hizentra (Biological) $130.09
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in New York
Dr. Stephen Krieger, Md, MD
Neurology — Payments: $1.6M
Neurology $1.6M
Dr. David Dodick, M.d, M.D
Neurology — Payments: $765,174
Neurology $765,174
Dr. David Simpson, M.d, M.D
Neurology — Payments: $638,492
Neurology $638,492
Steven Wolf, Md, MD
Neurology — Payments: $585,108
Neurology $585,108
Dr. Alexander Shtilbans, Md, Ph.d, MD, PH.D
Neurology — Payments: $550,165
Neurology $550,165
Dr. Fred Lublin, M.d, M.D
Neurology — Payments: $549,390
Neurology $549,390